November 29, 2021
November 29, 2021
SINGAPORE – Nov 29, 2021 – Lion TCR is pleased to announce that Scientific Founder & Chairman, Professor Antonio Bertoletti has been placed among some of the world’s most highly cited researchers, according to the Highly Cited Researchers 2021 List published by data analytics firm Clarivate.
This annual list recognizes 6,602 researchers from 70 countries and regions who have made significant contributions to their research fields through the publication of multiple highly cited articles during the last decade.
According to Clarivate's Web of Science citation index, publications by Highly Cited Researchers are in the top 1% by citations for field and publication year.
Data scientists and bibliometric experts at the Institute for Scientific Information at Clarivate perform analyses and analysis of data to determine the "who's who" of influential researchers. The tallies are also used to identify countries and research institutions where these citation elite are based.
National University of Singapore (NUS) luminaries in this year’s list are recognized for excellence across a wide range of disciplines, including Chemistry, Clinical Medicine, Computer Science, Economics and Business, Engineering, Materials Science, Neuroscience and Behaviour, Pharmacology and Toxicology, Physics and more.
For more information: https://news.nus.edu.sg/32-nus-scientists-among-the-worlds-most-highly-cited-researchers/
Lion TCR Announces Poster Presentation of Phase 1 Study for Lead Product LioCyx-M at AASLD The Liver Meeting 2022
Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma
Scientific Founder & Chairman, Professor Antonio Bertoletti Has Been Placed on Highly Cited Researchers 2021 List
Lion TCR Announces FDA Clearance of its IND Application for its Lead Investigational Product, LioCyx-M004, for Hepatocellular Carcinoma
Scientific Founder, Prof Antonio Bertoletti Appointed as Cellular Immunotherapy Infectious Diseases Lead for Singhealth Duke-NUS Cell Therapy Centre
Lion TCR Licenses and Duke-NUS Medical School ink an exclusive IP licensing agreement for Immunosuppressive Drug Resistant Anti-Cancer T-cells
Dr Wai Lu-En, Director of R&D, represented Lion TCR to share the latest developments to the Minister for Manpower and Second Minister for Trade and Industry Tan See Leng.
Scientific Founder, Prof Antonio Bertoletti Appointed in Cell and Gene Therapy Workgroup in Singapore
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient